Keeping in line with the biotech M&A frenzy seen for much of the year, Merck & Co., Inc. $MRK announced a deal Monday to buy Tilos Therapeutics. Only recently, the pharma giant agreed to buy Peloton Therapeutics in a deal valued at up to $2.2billion.